Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact Us
Announcement & Circular
Stock Information
02186.HK
2.95 0.02  (0.68%)
TradingVolume：685.5
08-28
2024
ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2024
Publisher：
08-15
2024
NOTICE OF BOARD MEETING
Publisher：
08-12
2024
DISCLOSEABLE TRANSACTION - THIRD PARTY INVESTMENT IN SHENZHEN LUYE - COMPLETION OF THE INITIAL INVESTMENT
Publisher：
08-05
2024
APPROVAL OBTAINED FOR INITIATING CLINICAL TRIALS FOR Innovative Dual TAAR1/5-HT2CR Agonist (LY03020)
Publisher：
08-05
2024
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024
Publisher：
07-28
2024
ERZOFRI (PALIPERIDONE PALMITATE) EXTENDED-RELEASE INJECTABLE SUSPENSION APPROVED BY THE FDA FOR TREATMENT OF SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER
Publisher：
07-23
2024
DISCLOSEABLE TRANSACTION THIRD PARTY INVESTMENT IN SHENZHEN LUYE
Publisher：
07-04
2024
MIMEIXIN (OXYCODONE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE SUSTAINED-RELEASE TABLETS) APPROVED FOR MARKETING IN CHINA
Publisher：
07-02
2024
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
Publisher：
06-27
2024
THE MANUFACTURING FACILITY OF PALIPERIDONE PALMITATE EXTENDED-RELEASE INJECTABLE SUSPENSION (LY03010) HAS PASSED PAI BY U.S. FDA WITH NO FDA-483 (78KB)
Publisher：
First
1
2
3
4
5
Last
Investors
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact Us
Stock Information
02186.HK
TradingVolume：685.5
2.95
0.02  (0.68%)
Announcement & Circular
08-28
2024
ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2024
08-15
2024
NOTICE OF BOARD MEETING
08-12
2024
DISCLOSEABLE TRANSACTION - THIRD PARTY INVESTMENT IN SHENZHEN LUYE - COMPLETION OF THE INITIAL INVESTMENT
08-05
2024
APPROVAL OBTAINED FOR INITIATING CLINICAL TRIALS FOR Innovative Dual TAAR1/5-HT2CR Agonist (LY03020)
08-05
2024
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024
07-28
2024
ERZOFRI (PALIPERIDONE PALMITATE) EXTENDED-RELEASE INJECTABLE SUSPENSION APPROVED BY THE FDA FOR TREATMENT OF SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER
07-23
2024
DISCLOSEABLE TRANSACTION THIRD PARTY INVESTMENT IN SHENZHEN LUYE
07-04
2024
MIMEIXIN (OXYCODONE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE SUSTAINED-RELEASE TABLETS) APPROVED FOR MARKETING IN CHINA
07-02
2024
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
06-27
2024
THE MANUFACTURING FACILITY OF PALIPERIDONE PALMITATE EXTENDED-RELEASE INJECTABLE SUSPENSION (LY03010) HAS PASSED PAI BY U.S. FDA WITH NO FDA-483 (78KB)
First
1
2
3
4
5
Last